| Literature DB >> 23746426 |
Kaori Miyazaki1, Yoichiro Abe, Hiroko Iwanari, Yota Suzuki, Takahiro Kikuchi, Takashi Ito, Jungo Kato, Osamu Kusano-Arai, Toshiyuki Takahashi, Shuhei Nishiyama, Hiroko Ikeshima-Kataoka, Shoji Tsuji, Takeshi Arimitsu, Yasuhiro Kato, Toshiko Sakihama, Yoshiaki Toyama, Kazuo Fujihara, Takao Hamakubo, Masato Yasui.
Abstract
Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23746426 DOI： 10.1016/j.jneuroim.2013.03.003
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478